Stone Crest Wealth Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Stone Crest Wealth Management, Inc.
- $228 Billion
- Q3 2025
A detailed history of Stone Crest Wealth Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Stone Crest Wealth Management, Inc. holds 24,977 shares of VRDN stock, worth $717,838. This represents 0.24% of its overall portfolio holdings.
Number of Shares
24,977
Previous 25,070
0.37%
Holding current value
$717,838
Previous $350 Million
53.79%
% of portfolio
0.24%
Previous 0.17%
Shares
8 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
81.6MCall Options Held
39.6KPut Options Held
94.3K-
Deep Track Capital, LP Greenwich, CT5.38MShares$155 Million3.65% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$137 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$127 Million8.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$125 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$112 Million12.69% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $1.15B
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...